教員業績データベース |
|
論文種別 | 原著 |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Grading of astrocytomas using the PRESTO (principles of echo-shifting with a train of observations) magnetic resonance imaging sequence. |
掲載誌名 | 正式名:Clinical neurology and neurosurgery 略 称:Clin Neurol Neurosurg ISSNコード:1872-6968(Electronic)0303-8467(Linking) |
掲載区分 | 国外 |
巻・号・頁 | 173,pp.91-95 |
著者・共著者 | Iida Tomoko, Tomogane Yusuke, Takagi Toshinori, Miyaji Yuki, Sakamoto Daisuke, Yoshida Yasunori, Ishikura Reiichi, Ando Kumiko, Nakagomi Nami, Hirota Seiichi, Yoshimura Shinichi |
発行年月 | 2018/07 |
概要 | OBJECTIVE:Changes in brain tissue can be detected sensitively using PRESTO (principles of echo-shifting with a train of observations) magnetic resonance imaging (MRI). The aim of this study was to evaluate the correlation between the proliferative ability of astrocytoma and intratumoral spotty signal voids seen as hypo-intense dots on PRESTO MRI.PATIENTS AND METHODS:Fifty-seven astrocytic tumors, comprising 14 astrocytomas, 12 anaplastic astrocytomas, and 31 glioblastomas, were included in this retrospective study. The tumors were classified independently by blinded radiologists according to the number of spotty signal voids detected on PRESTO-MRI as follows: spot-free (grade 0), less than 3 spots (grade 1), or more than 3 spots or a large spot (grade 2).RESULTS:Thirteen patients (92.9%) with astrocytoma were classified as PRESTO grade 0 and 1 patient (7.1%) was classified as grade 1. Seven patients (58.3%) with anaplastic astrocytoma were classified as PRESTO grade 0, 1 (8.3%) as grade 1, and 4 as grade 2 (33.3%). Three patients (9.7%) with glioblastoma were classified as grade 0, 6 (19.4%) as grade 1, and 22 (70.9%) as grade 2. There was a strong correlation between PRESTO tumor grade and the mean MIB-1 index.CONCLUSIONS:These results indicate that a grading system based on the number of spotty signal voids detected on PRESTO images would be useful for the diagnosis of astrocytic tumors and predicting their proliferative ability. |
DOI | 10.1016/j.clineuro.2018.07.016 |
PMID | 30096569 |